Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT plus Tislelizumab in advanced or metastatic NSCLC after prior immune checkpoint inhibitor failure
KCT0011677Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0011677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011677.